I gave you the ZoomLenz version of progress.
"I think that the supportive data that can be harvested from the ACTIV-5 final report, coupled with the CMML study findings, and including our possibly comparable results to Gohibic in treating stage 6 patients (ACTIV-5 treated stage 5 AND 6 patients), that the FDA may find enough safety and efficacy data to make a favorable decision on approving a resubmitted EUA application."
I know management is planning to update our progress to regulators overseas, also, and that may be more likely to get approval. Pfizer owns the FDA.